Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients
Sign Up to like & getrecommendations! Published in 2018 at "International Urology and Nephrology"
DOI: 10.1007/s11255-018-2062-z
Abstract: PurposeAnaemia and resistance to erythropoiesis-stimulating agents (ESAs) are common complications in haemodialysis (HD) patients. We investigated the role of hepcidin in the development of anaemia and ESA resistance/hyporesponsiveness and its relation to the plasma levels… read more here.
Keywords: erythropoiesis stimulating; hscrp; resistance; hepcidin ... See more keywords
Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-021-01623-6
Abstract: To assess the value of the texture analysis of fluorine-18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma (POR/M-OSCC) treated with cetuximab. A total of… read more here.
Keywords: treatment response; response; treated cetuximab; texture ... See more keywords
Improving response to out-of-hospital cardiac arrest: The verified responder program pilot.
Sign Up to like & getrecommendations! Published in 2020 at "Resuscitation"
DOI: 10.1016/j.resuscitation.2020.06.015
Abstract: BACKGROUND Survival following out-of-hospital cardiac arrest (OHCA) decreases as the interval from collapse to CPR and defibrillation increases. Innovative approaches are needed to reduce response intervals, especially for private locations. METHODS We undertook the Verified… read more here.
Keywords: verified responder; hospital cardiac; response; program ... See more keywords
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2018.1457516
Abstract: Abstract Background: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. Objectives: To determine the number needed to treat (NNT) to achieve a 75% and… read more here.
Keywords: pasi; severe psoriasis; cost; moderate severe ... See more keywords
In Ataxia-Telangiectasia, Oral Betamethasone Administration Ameliorates Lymphocytes Functionality through Modulation of the IL-7/IL-7Rα Axis Paralleling the Neurological Behavior: A Comparative Report of Two Cases
Sign Up to like & getrecommendations! Published in 2020 at "Immunological Investigations"
DOI: 10.1080/08820139.2020.1761379
Abstract: ABSTRACT Ataxia-Telangiectasia (A-T) is characterized by cerebellar neurodegeneration and immunodeficiency. Recent studies suggest that very low glucocorticoids (GCs) doses may help improve A-T neurological phenotype in some patients. Interestingly, in GCs studies an unexpected improvement… read more here.
Keywords: functionality; neurological behavior; ataxia telangiectasia; telangiectasia oral ... See more keywords
Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1304395
Abstract: Abstract Objectives: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK,… read more here.
Keywords: per responder; top glargine; cost per; responder ... See more keywords
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2070428
Abstract: ABSTRACT Background Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking. Research design and methods To assess the cost per responder of adalimumab biosimilars versus the… read more here.
Keywords: cost per; responder; cost; adalimumab biosimilars ... See more keywords
P0509CLINICAL ANALYSIS FOR PROGNOSTIC FACTORS BASED ON RESULTS OF VERY SHORT-TERM TREATMENT IN MEMBRANOUS NRPHROPATHY
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0509
Abstract: Membranous nephropathy (MN) is known to affect frequently in elderly patients. Since the duration of MN treatment is likely to be prolonged, it is desirable that the treatment duration would be shortened by the concomitant… read more here.
Keywords: high responder; prognostic factors; treatment; intensity ... See more keywords
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
Sign Up to like & getrecommendations! Published in 2023 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000871
Abstract: The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota transplant (FMT) in patients… read more here.
Keywords: fecal microbiota; refractory melanoma; responder;
Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis
Sign Up to like & getrecommendations! Published in 2018 at "PAIN"
DOI: 10.1097/j.pain.0000000000001324
Abstract: Abstract Integrating information on physical function and pain intensity into a composite measure may provide a useful method for assessing treatment efficacy in clinical trials of chronic pain. Accordingly, we evaluated composite outcomes in trials… read more here.
Keywords: physical function; pain intensity; pain; responder ... See more keywords
Development and testing of an alternative responder definition for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI)
Sign Up to like & getrecommendations! Published in 2023 at "RMD Open"
DOI: 10.1136/rmdopen-2022-002721
Abstract: Objectives Dryness, fatigue and joint/muscle pain are typically assessed in Sjögren’s trials using European Alliance of Associations for Rheumatology Sjögren’s Syndrome Patient Reported Index (ESSPRI). A Patient Acceptable Symptom State of 90%), white (90%), with… read more here.
Keywords: responder; gren syndrome; syndrome patient; patient reported ... See more keywords